Serum levels of 14‑3‑3η are associated with increased disease risk, activity and duration of rheumatoid arthritis in Chinese patients

The aim of the present study was to determine the association between serum 14-3-3η expression levels and disease risk, inflammation level and disease duration in Chinese patients with rheumatoid arthritis (RA). A total of 45 Chinese patients with RA, 45 patients with osteoarthritis (OA) and 44 age-...

Full description

Saved in:
Bibliographic Details
Published inExperimental and therapeutic medicine Vol. 20; no. 2; pp. 754 - 761
Main Authors Tu, Jianxin, Chen, Xiaowei, Dai, Meijie, Pan, Axiao, Liu, Cailong, Zhou, Yan, Xia, Xiaoru, Sun, Li
Format Journal Article
LanguageEnglish
Published Athens Spandidos Publications UK Ltd 01.08.2020
D.A. Spandidos
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The aim of the present study was to determine the association between serum 14-3-3η expression levels and disease risk, inflammation level and disease duration in Chinese patients with rheumatoid arthritis (RA). A total of 45 Chinese patients with RA, 45 patients with osteoarthritis (OA) and 44 age- and sex-matched (with the RA group) healthy control (HC) subjects were consecutively recruited for the present case-controlled study. In addition, the demographic and clinicopathological characteristics of the patients with RA were collected. Serum samples were obtained from patients with RA, patients with OA and the HCs, and the serum levels of 14-3-3η were determined by ELISA. Compared with that in the OA patients (P=0.006) and HCs (P<0.001), 14-3-3η expression was significantly increased in RA patients, and receiver operating characteristics (ROC) analysis indicated that it served as a potential predictive marker for the risk of RA. In patients with RA, serum levels of 14-3-3η were positively correlated with disease duration (P=0.003), erythrocyte sedimentation rate (P=0.006) and disease activity score in 28 joints (P=0.025). The proportion of rheumatoid factor (RF)-positive patients (P=0.023) and anti-citrullinated protein antibody (ACPA)-positive patients (P=0.002) with RA was increased (when 14-3-3η expression was increased) compared with RF-negative patients or ACPA-negative patients, respectively. Of note, 14-3-3η serum levels were able to distinguish patients with established RA (disease duration, >2 years) from patients with early RA (disease duration, ≤2 years) with an AUC of 0.759 (95% CI, 0.612-0.905), and the sensitivity and the specificity at the best cut-off point (14-3-3η=0.613 ng/ml) were 79.3 and 75.0%, respectively. Furthermore, 14-3-3η was able to differentiate between RF-positive RA patients and RF-negative patients or HCs. In conclusion, circulating 14-3-3η expression may serve as a novel biomarker for disease risk and activity of RA in Chinese patients.
AbstractList The aim of the present study was to determine the association between serum 14-3-3η expression levels and disease risk, inflammation level and disease duration in Chinese patients with rheumatoid arthritis (RA). A total of 45 Chinese patients with RA, 45 patients with osteoarthritis (OA) and 44 age- and sex-matched (with the RA group) healthy control (HC) subjects were consecutively recruited for the present case-controlled study. In addition, the demographic and clinicopathological characteristics of the patients with RA were collected. Serum samples were obtained from patients with RA, patients with OA and the HCs, and the serum levels of 14-3-3η were determined by ELISA. Compared with that in the OA patients (P=0.006) and HCs (P<0.001), 14-3-3η expression was significantly increased in RA patients, and receiver operating characteristics (ROC) analysis indicated that it served as a potential predictive marker for the risk of RA. In patients with RA, serum levels of 14-3-3η were positively correlated with disease duration (P=0.003), erythrocyte sedimentation rate (P=0.006) and disease activity score in 28 joints (P=0.025). The proportion of rheumatoid factor (RF)-positive patients (P=0.023) and anti-citrullinated protein antibody (ACPA)-positive patients (P=0.002) with RA was increased (when 14-3-3η expression was increased) compared with RF-negative patients or ACPA-negative patients, respectively. Of note, 14-3-3η serum levels were able to distinguish patients with established RA (disease duration, >2 years) from patients with early RA (disease duration, ≤2 years) with an AUC of 0.759 (95% CI, 0.612-0.905), and the sensitivity and the specificity at the best cut-off point (14-3-3η=0.613 ng/ml) were 79.3 and 75.0%, respectively. Furthermore, 14-3-3η was able to differentiate between RF-positive RA patients and RF-negative patients or HCs. In conclusion, circulating 14-3-3η expression may serve as a novel biomarker for disease risk and activity of RA in Chinese patients.The aim of the present study was to determine the association between serum 14-3-3η expression levels and disease risk, inflammation level and disease duration in Chinese patients with rheumatoid arthritis (RA). A total of 45 Chinese patients with RA, 45 patients with osteoarthritis (OA) and 44 age- and sex-matched (with the RA group) healthy control (HC) subjects were consecutively recruited for the present case-controlled study. In addition, the demographic and clinicopathological characteristics of the patients with RA were collected. Serum samples were obtained from patients with RA, patients with OA and the HCs, and the serum levels of 14-3-3η were determined by ELISA. Compared with that in the OA patients (P=0.006) and HCs (P<0.001), 14-3-3η expression was significantly increased in RA patients, and receiver operating characteristics (ROC) analysis indicated that it served as a potential predictive marker for the risk of RA. In patients with RA, serum levels of 14-3-3η were positively correlated with disease duration (P=0.003), erythrocyte sedimentation rate (P=0.006) and disease activity score in 28 joints (P=0.025). The proportion of rheumatoid factor (RF)-positive patients (P=0.023) and anti-citrullinated protein antibody (ACPA)-positive patients (P=0.002) with RA was increased (when 14-3-3η expression was increased) compared with RF-negative patients or ACPA-negative patients, respectively. Of note, 14-3-3η serum levels were able to distinguish patients with established RA (disease duration, >2 years) from patients with early RA (disease duration, ≤2 years) with an AUC of 0.759 (95% CI, 0.612-0.905), and the sensitivity and the specificity at the best cut-off point (14-3-3η=0.613 ng/ml) were 79.3 and 75.0%, respectively. Furthermore, 14-3-3η was able to differentiate between RF-positive RA patients and RF-negative patients or HCs. In conclusion, circulating 14-3-3η expression may serve as a novel biomarker for disease risk and activity of RA in Chinese patients.
The aim of the present study was to determine the association between serum 14-3-3η expression levels and disease risk, inflammation level and disease duration in Chinese patients with rheumatoid arthritis (RA). A total of 45 Chinese patients with RA, 45 patients with osteoarthritis (OA) and 44 age- and sex-matched (with the RA group) healthy control (HC) subjects were consecutively recruited for the present case-controlled study. In addition, the demographic and clinicopathological characteristics of the patients with RA were collected. Serum samples were obtained from patients with RA, patients with OA and the HCs, and the serum levels of 14-3-3η were determined by ELISA. Compared with that in the OA patients (P=0.006) and HCs (P<0.001), 14-3-3η expression was significantly increased in RA patients, and receiver operating characteristics (ROC) analysis indicated that it served as a potential predictive marker for the risk of RA. In patients with RA, serum levels of 14-3-3η were positively correlated with disease duration (P=0.003), erythrocyte sedimentation rate (P=0.006) and disease activity score in 28 joints (P=0.025). The proportion of rheumatoid factor (RF)-positive patients (P=0.023) and anti-citrullinated protein antibody (ACPA)-positive patients (P=0.002) with RA was increased (when 14-3-3η expression was increased) compared with RF-negative patients or ACPA-negative patients, respectively. Of note, 14-3-3η serum levels were able to distinguish patients with established RA (disease duration, >2 years) from patients with early RA (disease duration, ≤2 years) with an AUC of 0.759 (95% CI, 0.612-0.905), and the sensitivity and the specificity at the best cut-off point (14-3-3η=0.613 ng/ml) were 79.3 and 75.0%, respectively. Furthermore, 14-3-3η was able to differentiate between RF-positive RA patients and RF-negative patients or HCs. In conclusion, circulating 14-3-3η expression may serve as a novel biomarker for disease risk and activity of RA in Chinese patients.
Author Dai, Meijie
Zhou, Yan
Pan, Axiao
Xia, Xiaoru
Sun, Li
Tu, Jianxin
Chen, Xiaowei
Liu, Cailong
AuthorAffiliation 3 Department of Orthopaedic Sports Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
1 Department of Rheumatology and Immunology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
2 Department of Laboratory Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
AuthorAffiliation_xml – name: 1 Department of Rheumatology and Immunology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
– name: 3 Department of Orthopaedic Sports Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
– name: 2 Department of Laboratory Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
Author_xml – sequence: 1
  givenname: Jianxin
  surname: Tu
  fullname: Tu, Jianxin
  organization: Department of Rheumatology and Immunology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
– sequence: 2
  givenname: Xiaowei
  surname: Chen
  fullname: Chen, Xiaowei
  organization: Department of Rheumatology and Immunology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
– sequence: 3
  givenname: Meijie
  surname: Dai
  fullname: Dai, Meijie
  organization: Department of Laboratory Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
– sequence: 4
  givenname: Axiao
  surname: Pan
  fullname: Pan, Axiao
  organization: Department of Rheumatology and Immunology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
– sequence: 5
  givenname: Cailong
  surname: Liu
  fullname: Liu, Cailong
  organization: Department of Orthopaedic Sports Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
– sequence: 6
  givenname: Yan
  surname: Zhou
  fullname: Zhou, Yan
  organization: Department of Rheumatology and Immunology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
– sequence: 7
  givenname: Xiaoru
  surname: Xia
  fullname: Xia, Xiaoru
  organization: Department of Rheumatology and Immunology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
– sequence: 8
  givenname: Li
  surname: Sun
  fullname: Sun, Li
  organization: Department of Rheumatology and Immunology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China
BookMark eNptUb2O1DAQttAh7liupLdEQ8Eu_klip0FCK_6kkyiA2nKcWTJHYi-2s6frqOl4Gt6Ch-BJcO6WghOWLM9ovh-Nv4fkxAcPhDzmbCN1K55DnjaCCbbRquH3yBlXrVhzxuuTY81azU_JeUqXrJy64VrXD8ipFKoSUvAz8v0DxHmiIxxgTDTsKK9-f_shl_vrJ7URqE0pOLQZenqFeaDoXQSbSttjWgoaMX15Rq3LeMB8Ta0voznajMEvinGAebI5YF_08hAxYyoqdDugh0LfFyT4nB6R-zs7Jjg_vivy6fWrj9u364v3b95tX16snRQirzUXWklQPWNV1zktQUjrpNUdAKsFq1jLukY0jVZ1z5Xume7qdtfzFlSnGJcr8uJWdz93E_SueEc7mn3EycZrEyyafyceB_M5HIySWsvivSJPjwIxfJ0hZTNhcjCO1kOYkxGVZKytlKoL9Mkd6GWYoy_r3aAa1tRFc0XkLcrFkFKEnXGYb_6v-ONoODNL3KbEbZa4zRJ3Ya3vsP6u8H_8H0tFsOY
CitedBy_id crossref_primary_10_3892_etm_2023_12364
crossref_primary_10_5114_reum_2022_123669
crossref_primary_10_1515_rir_2024_0030
crossref_primary_10_1080_00325481_2022_2052626
crossref_primary_10_1016_j_ejr_2024_11_002
crossref_primary_10_2478_rir_2021_0012
ContentType Journal Article
Copyright Copyright Spandidos Publications UK Ltd. 2020
Copyright: © Tu et al.
Copyright: © Tu et al. 2020
Copyright_xml – notice: Copyright Spandidos Publications UK Ltd. 2020
– notice: Copyright: © Tu et al.
– notice: Copyright: © Tu et al. 2020
DBID AAYXX
CITATION
3V.
7RV
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AN0
BENPR
CCPQU
FYUFA
GHDGH
K9.
KB0
M0S
NAPCQ
PHGZM
PHGZT
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.3892/etm.2020.8761
DatabaseName CrossRef
ProQuest Central (Corporate)
ProQuest Nursing and Allied Health Journals - PSU access expires 11/30/25.
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
British Nursing Database
ProQuest Central
ProQuest One Community College
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
British Nursing Index with Full Text
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

ProQuest One Academic Middle East (New)
Database_xml – sequence: 1
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1792-1015
EndPage 761
ExternalDocumentID PMC7388387
10_3892_etm_2020_8761
GeographicLocations China
GeographicLocations_xml – name: China
GroupedDBID ---
0R~
53G
7RV
7X7
8FI
8FJ
AAKDD
AAYXX
ABDBF
ABJNI
ABUWG
ACGFS
ACUHS
ADBBV
AENEX
AFKRA
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AN0
BENPR
BKEYQ
BNQBC
BPHCQ
BVXVI
C45
CCPQU
CITATION
EBD
EBS
EJD
ESX
F5P
FYUFA
HMCUK
HUR
HZ~
IAO
IHR
IPNFZ
ITC
NAPCQ
O9-
OVD
PHGZM
PHGZT
PQQKQ
PROAC
RIG
RPM
TEORI
UKHRP
3V.
7XB
8FK
K9.
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c322t-812873e7d004bbc83e23ac3a8bee05204090b6266875d178d08b59fd19e7b7013
IEDL.DBID 7X7
ISSN 1792-0981
IngestDate Thu Aug 21 14:10:06 EDT 2025
Thu Jul 10 23:31:45 EDT 2025
Sun Jul 13 03:59:42 EDT 2025
Thu Apr 24 23:00:44 EDT 2025
Tue Jul 01 02:59:57 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 2
Language English
License This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c322t-812873e7d004bbc83e23ac3a8bee05204090b6266875d178d08b59fd19e7b7013
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Contributed equally
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC7388387
PMID 32742321
PQID 2430606588
PQPubID 2044959
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7388387
proquest_miscellaneous_2430094775
proquest_journals_2430606588
crossref_citationtrail_10_3892_etm_2020_8761
crossref_primary_10_3892_etm_2020_8761
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-08-01
PublicationDateYYYYMMDD 2020-08-01
PublicationDate_xml – month: 08
  year: 2020
  text: 2020-08-01
  day: 01
PublicationDecade 2020
PublicationPlace Athens
PublicationPlace_xml – name: Athens
PublicationTitle Experimental and therapeutic medicine
PublicationYear 2020
Publisher Spandidos Publications UK Ltd
D.A. Spandidos
Publisher_xml – name: Spandidos Publications UK Ltd
– name: D.A. Spandidos
SSID ssj0000561885
Score 2.218454
Snippet The aim of the present study was to determine the association between serum 14-3-3η expression levels and disease risk, inflammation level and disease duration...
SourceID pubmedcentral
proquest
crossref
SourceType Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 754
SubjectTerms Age
Biomarkers
Disease
Immunology
Patients
Proteins
Rheumatoid arthritis
Rheumatology
Signal transduction
Statistical analysis
Title Serum levels of 14‑3‑3η are associated with increased disease risk, activity and duration of rheumatoid arthritis in Chinese patients
URI https://www.proquest.com/docview/2430606588
https://www.proquest.com/docview/2430094775
https://pubmed.ncbi.nlm.nih.gov/PMC7388387
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NTtwwELYoXHqpoLTqFoqMhPa0Lokdx86pohUIVSpaIZD2FsU_q10JErpJDrwAr8Rb8EzMJN7d7qEcIzt2lBl7vhmPvyHkRKXGSRNLZiPFWTJNBDMytcwCtFZa2Eh0ZTr_XKWXt8nviZyEgFsd0iqXe2K3UbvKYoz8lCcAbtFe6h8PfxlWjcLT1VBC4x3ZQeoyTOlSE7WKsSA61l1VTlA7zqJMxz3NJlhpfuobvInOo--wIcSbZmmNNTczJf8xPRe75EPAjPSsF_Ie2fLlRzIc96TTjyN6s75DVY_okI7XdNSP--QJtoP2nt5hdlBNqymNEyaYeHmmxcLTIojHO4ohWTovEUbW8BiObigmn48o3n_AMhO0KKGp7fUGR1vMfAuot5o7GK-ZdRxJMArFwtweXg_ErfUncntxfvPrkoXqC8zCIm8YWH6thFcOlpExVgvPRWFFoY33mDwDjmFkwB1KweNxsdIu0kZmUxdnXhkFyPIz2S6r0n8hNJHcS7CULsrwYFib1GWaF1byxIJ28AEZLX9-bgM1OVbIuMvBRUFZ5SCrHGWVo6wGZLjq_tBzcvyv4-FSknlYmnW-VqQBOV41w6LCk5Ki9FXb9wG_Vyk5IGpDA1YTIi33Zks5n3X03EpoLbT6-vbkB-Q9fmefS3hItptF678BvmnMUafER2Tn5_nV-PoVxU39hg
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6V9AAXVF4iUGCRIKcstXdt7_qAEI9WKW2jCKVSb8b7iBKp2G1sC-UP8HO48i_4Tcz4kZAD3HqMdrOOMp9nvtmd_YaQVzLSNtR-yIwnOQtmgWA6jAwzQK2lEsYTdZvOs3E0Og8-X4QXO-RndxcGyyo7n1g7apsb3CM_4AGQW4yX6t3VNcOuUXi62rXQaGBx4lbfIWUr3h5_Avu-5vzocPpxxNquAswAeEsGEU1J4aQFeGhtlHBcpEakSjuHRSGQ8HgaaH4ETN76UllP6TCeWT92UktgTLDuLbIbCEhlemT3w-F48mW9q4N8XNV9QAHonHmx8hthT-AF_MCVePede2_ABfnbgXDDbrdrM_8Kdkd75G7LUun7Blb3yI7L7pPBpJG5Xg3pdHNrqxjSAZ1sBLBXD8gPcEDVN3qJ9UgFzWfUD5hg4vcvmi4dTVtAOEtxE5guMiSuBXxsD4solrsPKd64wMYWNM1gqGqQiqst564Cnp0vLKxXzmtVJliFYitwB19vpWKLh-T8RizziPSyPHOPCQ1C7kKIzdaL8Sha6cjGiqcm5IEBPPI-GXZ_fmJaMXTsyXGZQFKEtkrAVgnaKkFb9clgPf2qUQH518T9zpJJ6wyKZAPdPnm5HobXGM9m0szlVTMHMm0pwz6RWwhYPxCFwLdHssW8FgSXQimh5JP_P_wFuT2anp0mp8fjk6fkDv7mppJxn_TKZeWeAbsq9fMW0pR8vem36A9tVThu
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NjtMwELaWRUJcEL-isICRoKeaJnYcOweEEEu1y8Kqh12ptxD_VK20myxNItQX4JWQeAieiZn8tPQAtz1Gdp2o83nmsz3-hpBXKjZOmlAyGyjOonkkmJGxZRaotdLCBqIp0_nlND46jz7N5GyP_OrvwmBaZe8TG0ftCot75GMeAbnFeKnH8y4tYno4eXf1jWEFKTxp7ctptBA58evvsHwr3x4fgq1fcz75ePbhiHUVBpgFIFcMoptWwisHUDHGauG5yKzItPEeE0Rg8RMYoPwxsHoXKu0CbWQyd2HilVHAnmDcG-SmEjLEOaZmarO_g8xcNxVBAfKcBYkOW4lPYAh87Cu8Bc-DN-CMwt2QuOW5u1maf4W9yV1yp-Or9H0LsHtkz-f3yXDaCl6vR_Rse3-rHNEhnW6lsNcPyA9wRfUlvcDMpJIWcxpGTDDx-yfNVp5mHTS8o7gdTJc5UtgSHrtjI4qJ7yOKdy-wxAXNcmiqW8ziaKuFr4FxF0sH41WLRp8JRqFYFNzDzzvR2PIhOb8Wuzwi-3mR-8eERpJ7CVHaBQkeSmsTu0TzzEoeWUAmH5BR_-entpNFx-ocFyksj9BWKdgqRVulaKsBGW66X7V6IP_qeNBbMu3cQpluQTwgLzfNMKHxlCbLfVG3fWDNrZQcELWDgM0LURJ8tyVfLhppcCW0Flo9-f_LX5BbMHfSz8enJ0_JbfzkNqXxgOxXq9o_A5pVmecNnin5et0T6A94hDs-
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+levels+of+14-3-3%CE%B7+are+associated+with+increased+disease+risk%2C+activity+and+duration+of+rheumatoid+arthritis+in+Chinese+patients&rft.jtitle=Experimental+and+therapeutic+medicine&rft.au=Tu%2C+Jianxin&rft.au=Chen%2C+Xiaowei&rft.au=Dai%2C+Meijie&rft.au=Pan%2C+Axiao&rft.date=2020-08-01&rft.pub=Spandidos+Publications+UK+Ltd&rft.issn=1792-0981&rft.eissn=1792-1015&rft.volume=20&rft.issue=2&rft.spage=754&rft.epage=761&rft_id=info:doi/10.3892%2Fetm.2020.8761&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1792-0981&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1792-0981&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1792-0981&client=summon